MYCIT

Welcome to the Brand page for “MYCIT”, which is offered here for Scientific apparatuses and instruments, next generation sequencers for laboratory research use; software algorithms, downloadable software programs for use in analyzing next generation sequencer data, in particular for the detection and collection of mutations in cancer patients;pharmaceutical products for the treatment of cancer, in particular based on nucleic acids and/or proteins; personalised patient-specific medicinal products, in particular based on nucleic acids and/or proteins, pharmaceutical preparations for treatment of cancer diseases, autoimmune diseases, and infectious diseases;medical, veterinary-medical and pharmaceutical advisory services, in particular in the selection of suitable treatments for cancer diseases of all kinds; medical services, performance of analyses and treatments as part of personalised cancer immunotherapy; medical services for the treatment of cancer, provision of treatments based on nucleic acids and/or checkpoint inhibitors;high-throughput analytical instruments, in particular instruments for next-generation sequencing (ngs) for medical issues, as well as for gene expression profiling and for the detection of epigenetic changes, high throughput genome and exome gene sequencers for medical use;medical research and development in the field of cancer immunotherapy, in particular research and development in the field of human and veterinary medical diagnostics and treatment by means of molecular-biological, genetic, biotechnological and/or bioinformatic methods, in particular by means of next-generation sequencing; scientific laboratory services and scientific research services featuring diagnostics of tumour markers for personalised treatment;.

Its status is currently believed to be active. Its class is unavailable. “MYCIT” is believed to be currently owned by “BioNTech SE”.